Osteoarthritis
Conditions
Interventions
Control Group:Sodium hyaluronate is injected into the joint cavity once a week for 8 weeks
Experimental Group:Chlorphenamine maleate combined with sodium hyaluronate are injected into the articular cavity once a week for 8 weeks
Sponsors
Department of Cell Biology, School of Basic Medicine, Southern Medical University, Guangdong Key Laboratory of Bone and Joint Degenerative Diseases
Eligibility
Sex/Gender
All
Age
No minimum to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 20mm in the past week; 5. The patient agrees and can tolerate X-ray plain film scanning; 6. The patient agrees to undergo MRI testing; 7. The patients voluntarily participate in the research and can provide written informed consent; 8. Patients may receive telephone interviews or visit the hospital for follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant patients or positive pregnancy test, nursing status; 2. Patients with rheumatoid arthritis and other autoimmune diseases or serious diseases, such as: psoriatic arthritis, lupus, active cancer, severe cardiovascular and kidney diseases, etc.; 3. Those with bleeding tendency or coagulation dysfunction; 4. Skin disease or skin infection around the site to be injected, and knee joint infection, surgery and radiotherapy within the past three months; 5. Those who have used intra-articular injection, intramuscular injection and oral glucocorticoid or sodium hyaluronate or all histamine H1 receptor antagonists within the past 3 months; 6. Have a history of allergic reaction to any ingredient in the study drug; 7. Contraindications of MRI such as pacemaker, artificial metal valve, aneurysm clipping, arterial dissection, claustrophobia, etc.; 8. Those who are participating in and affecting other research experiments that affect the results of this research; 9. The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Western Ontario McMasters Osteoarthritis Index (WOMAC); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptom score;Loss of knee cartilage volume;Change in bone marrow lesions;Change in joint effusion;X-Ray examination;Changes of inflammatory factors in blood; | — |
Countries
China
Contacts
Public ContactBai Xiaochun
Department of Cell Biology, School of Basic Medicine, Southern Medical University, Guangdong Key Laboratory of Bone and Joint Degenerative Diseases
Outcome results
None listed